| 1 | Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast Cancer | 3.8 | 8 | Citations (PDF) |
| 2 | Re-epithelialization of cancer cells increases autophagy and DNA damage: Implications for breast cancer dormancy and relapse | 5.4 | 7 | Citations (PDF) |
| 3 | The Power and Promise of Patient-Derived Xenografts of Human Breast Cancer | 6.6 | 10 | Citations (PDF) |
| 4 | Predictability of B cell clonal persistence and immunosurveillance in breast cancer | 23.5 | 23 | Citations (PDF) |
| 5 | Development and validation of a reliable DNA copy-number-based machine learning algorithm (CopyClust) for breast cancer integrative cluster classification | 3.4 | 4 | Citations (PDF) |
| 6 | A deep-learning framework to predict cancer treatment response from histopathology images through imputed transcriptomics | 22.5 | 131 | Citations (PDF) |
| 7 | Gene expression signature for predicting homologous recombination deficiency in triple-negative breast cancer | 6.4 | 7 | Citations (PDF) |
| 8 | Comparison of tumor‐informed and tumor‐naïve sequencing assays for ctDNA detection in breast cancer | 7.1 | 55 | Citations (PDF) |
| 9 | Obesity-associated changes in molecular biology of primary breast cancer | 13.7 | 55 | Citations (PDF) |
| 10 | Vitamin B5 supports MYC oncogenic metabolism and tumor progression in breast cancer | 17.1 | 58 | Citations (PDF) |
| 11 | Clinical utility of whole-genome sequencing in precision oncology | 13.7 | 59 | Citations (PDF) |
| 12 | Analytical demands to use whole-genome sequencing in precision oncology | 13.7 | 50 | Citations (PDF) |
| 13 | Clinical interpretation of whole-genome and whole-transcriptome sequencing for precision oncology | 13.7 | 26 | Citations (PDF) |
| 14 | Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients | 27.4 | 427 | Citations (PDF) |
| 15 | Nucleoporin-93 reveals a common feature of aggressive breast cancers: robust nucleocytoplasmic transport of transcription factors | 6.3 | 26 | Citations (PDF) |
| 16 | Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation | 3.4 | 10 | Citations (PDF) |
| 17 | With one eye on the future | 33.0 | 0 | Citations (PDF) |
| 18 | Preclinical
In Vivo
Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification | 3.8 | 98 | Citations (PDF) |
| 19 | Breast tumor microenvironment structures are associated with genomic features and clinical outcome | 25.2 | 241 | Citations (PDF) |
| 20 | Allelic expression imbalance of PIK3CA mutations is frequent in breast cancer and prognostically significant | 6.4 | 6 | Citations (PDF) |
| 21 | eQTL Set–Based Association Analysis Identifies Novel Susceptibility Loci for Barrett Esophagus and Esophageal Adenocarcinoma | 1.1 | 7 | Citations (PDF) |
| 22 | Germline allelic expression of genes at 17q22 locus associates with risk of breast cancer | 4.9 | 2 | Citations (PDF) |
| 23 | Copy number heterogeneity identifies ER+ breast cancer patients that do not benefit from adjuvant endocrine therapy | 5.5 | 2 | Citations (PDF) |
| 24 | The impact of AI on researchCell, 2022, 185, 2621-2622 | 33.6 | 12 | Citations (PDF) |
| 25 | Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance | 6.8 | 56 | Citations (PDF) |
| 26 | High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer | 13.7 | 100 | Citations (PDF) |
| 27 | Clonal somatic copy number altered driver events inform drug sensitivity in high-grade serous ovarian cancer | 13.7 | 38 | Citations (PDF) |
| 28 | Androgen receptor function and targeted therapeutics across breast cancer subtypes | 4.7 | 78 | Citations (PDF) |
| 29 | Implementation of Whole-Genome and Transcriptome Sequencing Into Clinical Cancer Care | 1.9 | 55 | Citations (PDF) |
| 30 | Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy | 4.6 | 46 | Citations (PDF) |
| 31 | NRG1 fusions in breast cancer | 4.7 | 27 | Citations (PDF) |
| 32 | FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1 | 4.7 | 44 | Citations (PDF) |
| 33 | Time-resolved single-cell analysis of Brca1 associated mammary tumourigenesis reveals aberrant differentiation of luminal progenitors | 13.7 | 79 | Citations (PDF) |
| 34 | Landscapes of cellular phenotypic diversity in breast cancer xenografts and their impact on drug response | 13.7 | 58 | Citations (PDF) |
| 35 | PI3K activation promotes resistance to eribulin in HER2-negative breast cancer | 5.5 | 16 | Citations (PDF) |
| 36 | Characterisation of PALB2 tumours through whole-exome and whole-transcriptomic analyses | 6.4 | 9 | Citations (PDF) |
| 37 | Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment | 13.3 | 147 | Citations (PDF) |
| 38 | Deciphering the signaling network of breast cancer improves drug sensitivity prediction | 5.8 | 39 | Citations (PDF) |
| 39 | TSHZ2 is an EGF-regulated tumor suppressor that binds to the cytokinesis regulator PRC1 and inhibits metastasis | 5.4 | 19 | Citations (PDF) |
| 40 | High-throughput surface marker screen on primary human breast tissues reveals further cellular heterogeneity | 4.7 | 14 | Citations (PDF) |
| 41 | The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers | 6.4 | 6 | Citations (PDF) |
| 42 | Clonal fitness inferred from time-series modelling of single-cell cancer genomes | 37.9 | 148 | Citations (PDF) |
| 43 | Functional genomics approaches to improve pre‐clinical drug screening and biomarker discovery | 7.1 | 14 | Citations (PDF) |
| 44 | Circulating tumor DNA is readily detectable among Ghanaian breast cancer patients supporting non-invasive cancer genomic studies in Africa | 6.5 | 9 | Citations (PDF) |
| 45 | Metabolic imaging with hyperpolarized [1-13C] pyruvate in patient-derived preclinical mouse models of breast cancer | 1.1 | 4 | Citations (PDF) |
| 46 | 3D deformable registration of longitudinal abdominopelvic CT images using unsupervised deep learning | 4.6 | 17 | Citations (PDF) |
| 47 | DNA methylation landscapes of 1538 breast cancers reveal a replication-linked clock, epigenomic instability and cis-regulation | 13.7 | 77 | Citations (PDF) |
| 48 | Germline
APOBEC3B
deletion increases somatic hypermutation in Asian breast cancer that is associated with Her2 subtype,
PIK3CA
mutations and immune activation | 4.3 | 29 | Citations (PDF) |
| 49 | Clonal populations of a human TNBC model display significant functional heterogeneity and divergent growth dynamics in distinct contexts | 6.5 | 7 | Citations (PDF) |
| 50 | Hyperpolarized Carbon-13 MRI for Early Response Assessment of Neoadjuvant Chemotherapy in Breast Cancer Patients | 3.8 | 45 | Citations (PDF) |
| 51 | Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma | 33.0 | 245 | Citations (PDF) |
| 52 | Positive correlation between transcriptomic stemness and PI3K/AKT/mTOR signaling scores in breast cancer, and a counterintuitive relationship with PIK3CA genotype | 3.2 | 29 | Citations (PDF) |
| 53 | Multi-omic machine learning predictor of breast cancer therapy response | 37.9 | 571 | Citations (PDF) |
| 54 | ARID1A influences HDAC1/BRD4 activity, intrinsic proliferative capacity and breast cancer treatment response | 25.2 | 163 | Citations (PDF) |
| 55 | Association Between Levels of Sex Hormones and Risk of Esophageal Adenocarcinoma and Barrett’s Esophagus | 6.0 | 24 | Citations (PDF) |
| 56 | Metabolic Imaging Detects Resistance to PI3Kα Inhibition Mediated by Persistent FOXM1 Expression in ER+ Breast Cancer | 33.0 | 50 | Citations (PDF) |
| 57 | Hyperpolarized 13C MRI of Tumor Metabolism Demonstrates Early Metabolic Response to Neoadjuvant Chemotherapy in Breast Cancer | 3.5 | 59 | Citations (PDF) |
| 58 | Towards a cancer mission in Horizon Europe: recommendations | 4.1 | 44 | Citations (PDF) |
| 59 | Landscape of G-quadruplex DNA structural regions in breast cancer | 25.2 | 198 | Citations (PDF) |
| 60 | Sex differences in oncogenic mutational processes | 13.7 | 92 | Citations (PDF) |
| 61 | Sex-Specific Genetic Associations for Barrett’s Esophagus and Esophageal Adenocarcinoma | 0.9 | 24 | Citations (PDF) |
| 62 | Association of Sperm-Associated Antigen 5 and Treatment Response in Patients With Estrogen Receptor–Positive Breast Cancer | 6.6 | 2 | Citations (PDF) |
| 63 | Age-correlated protein and transcript expression in breast cancer and normal breast tissues is dominated by host endocrine effects | 22.5 | 16 | Citations (PDF) |
| 64 | Transcriptional profiling reveals a subset of human breast tumors that retain wt
TP53
but display mutant p53‐associated features | 4.1 | 10 | Citations (PDF) |
| 65 | Trial watch : the gut microbiota as a tool to boost the clinical efficacy of anticancer immunotherapy | 5.4 | 31 | Citations (PDF) |
| 66 | ctDNA monitoring using patient-specific sequencing and integration of variant reads | 12.5 | 184 | Citations (PDF) |
| 67 | Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue | 6.3 | 71 | Citations (PDF) |
| 68 | The GATA3 X308_Splice breast cancer mutation is a hormone context-dependent oncogenic driver | 6.5 | 19 | Citations (PDF) |
| 69 | Cancer-associated fibroblast compositions change with breast cancer progression linking the ratio of S100A4+ and PDPN+ CAFs to clinical outcome | 22.5 | 305 | Citations (PDF) |
| 70 | Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal | 33.0 | 80 | Citations (PDF) |
| 71 | Imaging breast cancer using hyperpolarized carbon-13 MRI | 7.5 | 183 | Citations (PDF) |
| 72 | Imaging mass cytometry and multiplatform genomics define the phenogenomic landscape of breast cancer | 22.5 | 311 | Citations (PDF) |
| 73 | A network analysis to identify mediators of germline-driven differences in breast cancer prognosis | 13.7 | 36 | Citations (PDF) |
| 74 | Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts | 6.8 | 37 | Citations (PDF) |
| 75 | The molecular landscape of Asian breast cancers reveals clinically relevant population-specific differences | 13.7 | 91 | Citations (PDF) |
| 76 | DNA copy number motifs are strong and independent predictors of survival in breast cancer | 4.4 | 13 | Citations (PDF) |
| 77 | Deep Sequencing of B Cell Receptor Repertoires From COVID-19 Patients Reveals Strong Convergent Immune Signatures | 4.9 | 146 | Citations (PDF) |
| 78 | Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer | 12.5 | 284 | Citations (PDF) |
| 79 | BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer | 6.8 | 23 | Citations (PDF) |
| 80 | POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients | 6.8 | 24 | Citations (PDF) |
| 81 | Clonal Decomposition and DNA Replication States Defined by Scaled Single-Cell Genome SequencingCell, 2019, 179, 1207-1221.e22 | 33.6 | 270 | Citations (PDF) |
| 82 | Cancer Core Europe: A translational research infrastructure for a European mission on cancer | 4.1 | 46 | Citations (PDF) |
| 83 | The circular RNome of primary breast cancer | 4.6 | 101 | Citations (PDF) |
| 84 | Chlorambucil targets
BRCA
1/2‐deficient tumours and counteracts
PARP
inhibitor resistance | 7.1 | 35 | Citations (PDF) |
| 85 | Chromosome 12p Amplification in Triple-Negative/
BRCA1-
Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity | 3.8 | 20 | Citations (PDF) |
| 86 | EN1
Is a Transcriptional Dependency in Triple-Negative Breast Cancer Associated with Brain Metastasis | 3.8 | 61 | Citations (PDF) |
| 87 | 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial | 62.1 | 281 | Citations (PDF) |
| 88 | The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer | 6.3 | 114 | Citations (PDF) |
| 89 | A key genomic subtype associated with lymphovascular invasion in invasive breast cancer | 5.5 | 35 | Citations (PDF) |
| 90 | EZH2 Is Overexpressed in
BRCA1
-like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy | 6.8 | 43 | Citations (PDF) |
| 91 | PDLIM2 Is a Marker of Adhesion and β-Catenin Activity in Triple-Negative Breast Cancer | 3.8 | 21 | Citations (PDF) |
| 92 | Cancer Treatment in the Genomic Era | 17.4 | 32 | Citations (PDF) |
| 93 | Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups | 37.9 | 373 | Citations (PDF) |
| 94 | Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer | 4.8 | 74 | Citations (PDF) |
| 95 | No Association Between Vitamin D Status and Risk of Barrett's Esophagus or Esophageal Adenocarcinoma: A Mendelian Randomization Study | 6.0 | 19 | Citations (PDF) |
| 96 | Genome-wide association study of germline variants and breast cancer-specific mortality | 5.5 | 62 | Citations (PDF) |
| 97 | Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy | 13.7 | 52 | Citations (PDF) |
| 98 | Tumor diversity and the trade-off between universal cancer tasks | 13.7 | 79 | Citations (PDF) |
| 99 | PathTracer: High-sensitivity detection of differential pathway activity in tumours | 3.4 | 6 | Citations (PDF) |
| 100 | The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper | 5.0 | 256 | Citations (PDF) |
| 101 | Next Generation-Targeted Amplicon Sequencing (NG-TAS): an optimised protocol and computational pipeline for cost-effective profiling of circulating tumour DNA | 9.6 | 106 | Citations (PDF) |
| 102 | Fbxl17 is rearranged in breast cancer and loss of its activity leads to increased global O-GlcNAcylation | 5.5 | 10 | Citations (PDF) |
| 103 | High USP6NL Levels in Breast Cancer Sustain Chronic AKT Phosphorylation and GLUT1 Stability Fueling Aerobic Glycolysis | 3.8 | 72 | Citations (PDF) |
| 104 | SILAC identifies LAD1 as a filamin-binding regulator of actin dynamics in response to EGF and a marker of aggressive breast tumors | 5.4 | 50 | Citations (PDF) |
| 105 | Determining Risk of Barrett’s Esophagus and Esophageal Adenocarcinoma Based on Epidemiologic Factors and Genetic Variants | 0.9 | 78 | Citations (PDF) |
| 106 | Promoter of lncRNA Gene PVT1 Is a Tumor-Suppressor DNA Boundary ElementCell, 2018, 173, 1398-1412.e22 | 33.6 | 460 | Citations (PDF) |
| 107 | Germline pathogenic variants in PALB2 and other cancer-predisposing genes in families with hereditary diffuse gastric cancer without CDH1 mutation: a whole-exome sequencing study | 22.8 | 95 | Citations (PDF) |
| 108 | Shallow whole genome sequencing for robust copy number profiling of formalin-fixed paraffin-embedded breast cancers | 2.7 | 30 | Citations (PDF) |
| 109 | Interactions Between Genetic Variants and Environmental Factors Affect Risk of Esophageal Adenocarcinoma and Barrett’s Esophagus | 6.0 | 20 | Citations (PDF) |
| 110 | Comparative study of endoscopic surveillance in hereditary diffuse gastric cancer according to CDH1 mutation status | 1.8 | 98 | Citations (PDF) |
| 111 | Cancer Core Europe: A European cancer research alliance realizing a research infrastructure with critical mass and programmatic approach to cure cancer in the 21st century | 4.9 | 17 | Citations (PDF) |
| 112 | Computational approach to discriminate human and mouse sequences in patient-derived tumour xenografts | 3.3 | 74 | Citations (PDF) |
| 113 | Effects of Collection and Processing Procedures on Plasma Circulating Cell-Free DNA from Cancer Patients | 2.5 | 110 | Citations (PDF) |
| 114 | MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models | 12.4 | 130 | Citations (PDF) |
| 115 | αE‐catenin is a candidate tumor suppressor for the development of E‐cadherin‐expressing lobular‐type breast cancer | 4.9 | 48 | Citations (PDF) |
| 116 | Dynamics of multiple resistance mechanisms in plasma DNA during EGFR‐targeted therapies in non‐small cell lung cancer | 7.1 | 68 | Citations (PDF) |
| 117 | Saccharomyces cerevisiae-like 1 (SEC14L1) is a prognostic factor in breast cancer associated with lymphovascular invasion | 4.8 | 18 | Citations (PDF) |
| 118 | Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells | 16.3 | 409 | Citations (PDF) |
| 119 | SOX4 can redirect TGF-β-mediated SMAD3-transcriptional output in a context-dependent manner to promote tumorigenesis | 15.5 | 59 | Citations (PDF) |
| 120 | Weibull regression with Bayesian variable selection to identify prognostic tumour markers of breast cancer survival | 1.6 | 29 | Citations (PDF) |
| 121 | Interrogating open issues in cancer precision medicine with patient-derived xenografts | 60.7 | 632 | Citations (PDF) |
| 122 | Liquid biopsies come of age: towards implementation of circulating tumour DNA | 60.7 | 2,552 | Citations (PDF) |
| 123 | High-risk individuals’ perceptions of reproductive genetic testing for CDH1 mutations | 1.4 | 9 | Citations (PDF) |
| 124 | CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours | 13.7 | 516 | Citations (PDF) |
| 125 | Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections | 2.3 | 55 | Citations (PDF) |
| 126 | Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial | 27.4 | 20 | Citations (PDF) |
| 127 | Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer | 3.8 | 94 | Citations (PDF) |
| 128 | Central pathology review with two-stage quality assurance for pathological response after neoadjuvant chemotherapy in the ARTemis Trial | 4.8 | 16 | Citations (PDF) |
| 129 | Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome | 4.7 | 98 | Citations (PDF) |
| 130 | Germline variation in inflammation-related pathways and risk of Barrett's oesophagus and oesophageal adenocarcinoma | 16.8 | 46 | Citations (PDF) |
| 131 | Somatic mutations reveal asymmetric cellular dynamics in the early human embryo | 37.9 | 293 | Citations (PDF) |
| 132 | PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models | 3.8 | 124 | Citations (PDF) |
| 133 | Rho-GTPase activating-protein 18: a biomarker associated with good prognosis in invasive breast cancer | 5.5 | 16 | Citations (PDF) |
| 134 | A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer | 25.2 | 524 | Citations (PDF) |
| 135 | Breast Cancer Molecular Stratification | 3.4 | 248 | Citations (PDF) |
| 136 | Therapeutic relevance of the PP2A-B55 inhibitory kinase MASTL/Greatwall in breast cancer | 13.3 | 72 | Citations (PDF) |
| 137 | Intersect-then-combine approach: improving the performance of somatic variant calling in whole exome sequencing data using multiple aligners and callers | 9.6 | 56 | Citations (PDF) |
| 138 | The Psychosocial Impact of Undergoing Prophylactic Total Gastrectomy (PTG) to Manage the Risk of Hereditary Diffuse Gastric Cancer (HDGC) | 1.7 | 34 | Citations (PDF) |
| 139 | Further evidence to support bimodality of oestrogen receptor expression in breast cancer | 3.6 | 17 | Citations (PDF) |
| 140 | Body mass index and breast cancer survival: a Mendelian randomization analysis | 4.9 | 57 | Citations (PDF) |
| 141 | Integrative analysis of copy number and gene expression in breast cancer using formalin-fixed paraffin-embedded core biopsy tissue: a feasibility study | 3.3 | 13 | Citations (PDF) |
| 142 | The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting | 4.7 | 68 | Citations (PDF) |
| 143 | Patterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study | 8.0 | 576 | Citations (PDF) |
| 144 | Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer | 4.7 | 17 | Citations (PDF) |
| 145 | Subtype‐specific micro‐RNA expression signatures in breast cancer progression | 4.3 | 62 | Citations (PDF) |
| 146 | Stratification and therapeutic potential of PML in metastatic breast cancer | 13.7 | 57 | Citations (PDF) |
| 147 | Modeling Breast Cancer Intertumor and Intratumor Heterogeneity Using Xenografts | 1.6 | 8 | Citations (PDF) |
| 148 | Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer | 3.4 | 175 | Citations (PDF) |
| 149 | p120-catenin prevents multinucleation through control of MKLP1-dependent RhoA activity during cytokinesis | 13.7 | 26 | Citations (PDF) |
| 150 | High expression of Rsf-1 correlates with poor prognosis in breast cancer | 0.9 | 0 | Citations (PDF) |
| 151 | The C/EBPδ protein is stabilized by estrogen receptor α activity, inhibits SNAI2 expression and associates with good prognosis in breast cancer | 6.5 | 26 | Citations (PDF) |
| 152 | Decline in Antigenicity of Tumor Markers by Storage Time Using Pathology Sections Cut From Tissue Microarrays | 1.0 | 11 | Citations (PDF) |
| 153 | Landscape of somatic mutations in 560 breast cancer whole-genome sequences | 37.9 | 2,144 | Citations (PDF) |
| 154 | Androgen and Estrogen Receptors in Breast Cancer Coregulate Human UDP-Glucuronosyltransferases 2B15 and 2B17 | 3.8 | 61 | Citations (PDF) |
| 155 | Genome-wide association studies in oesophageal adenocarcinoma and Barrett's oesophagus: a large-scale meta-analysis | 27.4 | 168 | Citations (PDF) |
| 156 | Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis | 2.3 | 94 | Citations (PDF) |
| 157 | A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer CompoundsCell, 2016, 167, 260-274.e22 | 33.6 | 444 | Citations (PDF) |
| 158 | A genomic approach to therapeutic target validation identifies a glucose-lowering
GLP1R
variant protective for coronary heart disease | 12.5 | 113 | Citations (PDF) |
| 159 | Reliable gene expression profiling of formalin-fixed paraffin-embedded breast cancer tissue (FFPE) using cDNA-mediated annealing, extension, selection, and ligation whole-genome (DASL WG) assay | 1.7 | 12 | Citations (PDF) |
| 160 | Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration | 13.7 | 127 | Citations (PDF) |
| 161 | The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes | 13.7 | 1,545 | Citations (PDF) |
| 162 | Prognostic Value of MammaPrint
®
in Invasive Lobular Breast Cancer | 2.4 | 37 | Citations (PDF) |
| 163 | An investigation of the factors effecting high-risk individuals’ decision-making about prophylactic total gastrectomy and surveillance for hereditary diffuse gastric cancer (HDGC) | 1.4 | 31 | Citations (PDF) |
| 164 | SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis | 27.4 | 117 | Citations (PDF) |
| 165 | Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer | 4.7 | 84 | Citations (PDF) |
| 166 | Cell‐free circulating tumour DNA as a liquid biopsy in breast cancer | 4.1 | 113 | Citations (PDF) |
| 167 | Double-stranded microRNA mimics can induce length- and passenger strand–dependent effects in a cell type–specific manner | 3.8 | 36 | Citations (PDF) |
| 168 | MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours | 5.5 | 117 | Citations (PDF) |
| 169 | The Relationship between Common Genetic Markers of Breast Cancer Risk and Chemotherapy-Induced Toxicity: A Case-Control Study | 2.3 | 16 | Citations (PDF) |
| 170 | Navigator‐3, a modulator of cell migration, may act as a suppressor of breast cancer progression | 7.1 | 46 | Citations (PDF) |
| 171 | Context-Specific Effects of TGF-β/SMAD3 in Cancer Are Modulated by the Epigenome | 6.3 | 48 | Citations (PDF) |
| 172 | A nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities | 7.1 | 29 | Citations (PDF) |
| 173 | A co-culture genome-wide RNAi screen with mammary epithelial cells reveals transmembrane signals required for growth and differentiation | 4.7 | 24 | Citations (PDF) |
| 174 | Common germline polymorphisms associated with breast cancer-specific survival | 4.7 | 29 | Citations (PDF) |
| 175 | Polymorphisms in Genes of Relevance for Oestrogen and Oxytocin Pathways and Risk of Barrett’s Oesophagus and Oesophageal Adenocarcinoma: A Pooled Analysis from the BEACON Consortium | 2.3 | 10 | Citations (PDF) |
| 176 | BRCA1‐like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential | 4.1 | 62 | Citations (PDF) |
| 177 | Pathway‐based personalized analysis of breast cancer expression data | 4.1 | 43 | Citations (PDF) |
| 178 | Combined Single-Cell Functional and Gene Expression Analysis Resolves Heterogeneity within Stem Cell Populations | 16.4 | 446 | Citations (PDF) |
| 179 | Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium | 3.3 | 26 | Citations (PDF) |
| 180 | Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents | 4.7 | 74 | Citations (PDF) |
| 181 | Crowdsourcing the General Public for Large Scale Molecular Pathology Studies in Cancer | 9.7 | 59 | Citations (PDF) |
| 182 | BCL11A is a triple-negative breast cancer gene with critical functions in stem and progenitor cells | 13.7 | 152 | Citations (PDF) |
| 183 | A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer | 4.1 | 38 | Citations (PDF) |
| 184 | Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers | 3.8 | 527 | Citations (PDF) |
| 185 | Progesterone receptor modulates ERα action in breast cancer | 37.9 | 647 | Citations (PDF) |
| 186 | Maintaining Tumor Heterogeneity in Patient-Derived Tumor Xenografts | 3.8 | 324 | Citations (PDF) |
| 187 | Intra-Tumour Signalling Entropy Determines Clinical Outcome in Breast and Lung Cancer | 3.1 | 70 | Citations (PDF) |
| 188 | Hereditary Diffuse Gastric Cancer Syndrome | 14.3 | 655 | Citations (PDF) |
| 189 | Identification of Novel Genetic Markers of Breast Cancer Survival | 4.6 | 65 | Citations (PDF) |
| 190 | Synaptojanin 2 is a druggable mediator of metastasis and the gene is overexpressed and amplified in breast cancer | 5.4 | 63 | Citations (PDF) |
| 191 | Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial | 27.4 | 130 | Citations (PDF) |
| 192 | Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells | 4.6 | 99 | Citations (PDF) |
| 193 | Robust BRCA1‐like classification of copy number profiles of samples repeated across different datasets and platforms | 4.1 | 30 | Citations (PDF) |
| 194 | Lymphocyte Invasion in IC10/Basal-Like Breast Tumors Is Associated with Wild-Type
TP53 | 3.1 | 58 | Citations (PDF) |
| 195 | Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel—Response | 6.8 | 2 | Citations (PDF) |
| 196 | Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer | 13.7 | 454 | Citations (PDF) |
| 197 | APOBEC3B-Mediated Cytidine Deamination Is Required for Estrogen Receptor Action in Breast Cancer | 6.3 | 120 | Citations (PDF) |
| 198 | Targeting BRCA1‐BER deficient breast cancer by ATM or DNA‐PKcs blockade either alone or in combination with cisplatin for personalized therapy | 4.1 | 82 | Citations (PDF) |
| 199 | Genome-driven integrated classification of breast cancer validated in over 7,500 samples | 8.1 | 207 | Citations (PDF) |
| 200 | Amplification of TRIM44: Pairing a Prognostic Target With Potential Therapeutic Strategy | 4.6 | 41 | Citations (PDF) |
| 201 | Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients | 9.9 | 730 | Citations (PDF) |
| 202 | Inclusion of KI67 significantly improves performance of the PREDICT prognostication and prediction model for early breast cancer | 2.9 | 60 | Citations (PDF) |
| 203 | The Impact of Prophylactic Total Gastrectomy on Health-Related Quality of Life | 4.6 | 54 | Citations (PDF) |
| 204 | TP53
Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance | 6.8 | 293 | Citations (PDF) |
| 205 | Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel | 6.8 | 102 | Citations (PDF) |
| 206 | Prospective cohort study assessing outcomes of patients from families fulfilling criteria for hereditary diffuse gastric cancer undergoing endoscopic surveillance | 1.8 | 82 | Citations (PDF) |
| 207 | The Breast Cancer Oncogene EMSY Represses Transcription of Antimetastatic microRNA miR-31 | 13.3 | 60 | Citations (PDF) |
| 208 | Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data | 27.4 | 790 | Citations (PDF) |
| 209 | Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial | 27.4 | 113 | Citations (PDF) |
| 210 | Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research | 25.1 | 1,646 | Citations (PDF) |
| 211 | Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes | 36.3 | 422 | Citations (PDF) |
| 212 | Up‐regulation of the interferon‐related genes in BRCA2 knockout epithelial cells | 4.9 | 30 | Citations (PDF) |
| 213 | Cancer Core Europe: A consortium to address the cancer care – Cancer research continuum challenge | 4.9 | 28 | Citations (PDF) |
| 214 | Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation | 13.7 | 110 | Citations (PDF) |
| 215 | Nuclear CSPP1 expression defined subtypes of basal-like breast cancer | 5.5 | 11 | Citations (PDF) |
| 216 | JARID1B Is a Luminal Lineage-Driving Oncogene in Breast Cancer | 33.0 | 197 | Citations (PDF) |
| 217 | DNA polymerase β deficiency is linked to aggressive breast cancer: A comprehensive analysis of gene copy number, mRNA and protein expression in multiple cohorts | 4.1 | 35 | Citations (PDF) |
| 218 | Genomic and protein expression analysis reveals flap endonuclease 1 (FEN1) as a key biomarker in breast and ovarian cancer | 4.1 | 140 | Citations (PDF) |
| 219 | Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis | 25.2 | 339 | Citations (PDF) |
| 220 | Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution | 37.9 | 596 | Citations (PDF) |
| 221 | Genome-driven integrated classification of breast cancer validated in over 7,500 samples | 12.2 | 4 | Citations (PDF) |
| 222 | Imprinted Chromatin around DIRAS3 Regulates Alternative Splicing of GNG12-AS1, a Long Noncoding RNA | 6.5 | 76 | Citations (PDF) |
| 223 | Basic cancer research is essential for the success of personalised medicine | 4.9 | 19 | Citations (PDF) |
| 224 | A new genome‐driven integrated classification of breast cancer and its implications | 7.3 | 298 | Citations (PDF) |
| 225 | Signatures of mutational processes in human cancer | 37.9 | 9,399 | Citations (PDF) |
| 226 | Prognosis of early breast cancer by immunohistochemistry defined intrinsic sub-types in patients treated with adjuvant chemotherapy in the NEAT/BR9601 trial | 4.3 | 15 | Citations (PDF) |
| 227 | Video Q&A: molecular profiling of breast cancer | 7.1 | 0 | Citations (PDF) |
| 228 | Assessing excellence in translational cancer research: a consensus based framework | 6.4 | 8 | Citations (PDF) |
| 229 | Astronomical algorithms for automated analysis of tissue protein expression in breast cancer | 5.5 | 32 | Citations (PDF) |
| 230 | Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer | 34.5 | 2,109 | Citations (PDF) |
| 231 | The Implications of Clonal Genome Evolution for Cancer Medicine | 34.5 | 342 | Citations (PDF) |
| 232 | Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA | 37.9 | 1,574 | Citations (PDF) |
| 233 | The shaping and functional consequences of the microRNA landscape in breast cancer | 37.9 | 396 | Citations (PDF) |
| 234 | G-Quadruplex DNA as a Molecular Target for Induced Synthetic Lethality in Cancer Cells | 15.0 | 153 | Citations (PDF) |
| 235 | Genetic heterogeneity in breast cancer: the road to personalized medicine? | 7.1 | 49 | Citations (PDF) |
| 236 | A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett's esophagus | 25.2 | 188 | Citations (PDF) |
| 237 | Master regulators of FGFR2 signalling and breast cancer risk | 13.7 | 223 | Citations (PDF) |
| 238 | Improving Breast Cancer Survival Analysis through Competition-Based Multidimensional Modeling | 3.1 | 83 | Citations (PDF) |
| 239 | Circulating Tumor DNA to Monitor Metastatic Breast Cancer | 34.5 | 134 | Citations (PDF) |
| 240 | TOX3 Mutations in Breast Cancer | 2.3 | 27 | Citations (PDF) |
| 241 | Breast cancer susceptibility risk associations and heterogeneity by E-cadherin tumor tissue expression | 2.3 | 19 | Citations (PDF) |
| 242 | A Prognostic Gene Signature for Metastasis-Free Survival of Triple Negative Breast Cancer Patients | 2.3 | 66 | Citations (PDF) |
| 243 | Allele-specific expression analysis methods for high-density SNP microarray data | 4.7 | 16 | Citations (PDF) |
| 244 | Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial and Re: CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients | 4.6 | 36 | Citations (PDF) |
| 245 | Quantitative Image Analysis of Cellular Heterogeneity in Breast Tumors Complements Genomic Profiling | 12.5 | 393 | Citations (PDF) |
| 246 | Integrative analysis of genome-wide loss of heterozygosity and monoallelic expression at nucleotide resolution reveals disrupted pathways in triple-negative breast cancer | 4.6 | 266 | Citations (PDF) |
| 247 | A Sparse Regulatory Network of Copy-Number Driven Gene Expression Reveals Putative Breast Cancer Oncogenes | 3.0 | 28 | Citations (PDF) |
| 248 | Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers | 4.7 | 24 | Citations (PDF) |
| 249 | Phenotypic and functional characterisation of the luminal cell hierarchy of the mammary gland | 4.7 | 289 | Citations (PDF) |
| 250 | TOMM34 expression in early invasive breast cancer: a biomarker associated with poor outcome | 2.3 | 30 | Citations (PDF) |
| 251 | Sa1795 Using Expression Array Data to Elucidate the Molecular Phenotype of a Novel Oncogene and Identify a Therapeutic Strategy | 0.9 | 0 | Citations (PDF) |
| 252 | TGFβ induces the formation of tumour-initiating cells in claudinlow breast cancer | 13.7 | 104 | Citations (PDF) |
| 253 | Predict: a population-based validation of a prognostic model for early breast cancer that includes HER2 | 0.9 | 0 | Citations (PDF) |
| 254 | Structural analysis of the genome of breast cancer cell line ZR-75-30 identifies twelve expressed fusion genes | 3.3 | 40 | Citations (PDF) |
| 255 | Saliva samples are a viable alternative to blood samples as a source of DNA for high throughput genotyping | 1.7 | 147 | Citations (PDF) |
| 256 | Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer | 5.5 | 63 | Citations (PDF) |
| 257 | Differential oestrogen receptor binding is associated with clinical outcome in breast cancer | 37.9 | 2,247 | Citations (PDF) |
| 258 | DriverNet: uncovering the impact of somatic driver mutations on transcriptional networks in cancer | 8.1 | 285 | Citations (PDF) |
| 259 | Calling Sample Mix-Ups in Cancer Population Studies | 2.3 | 9 | Citations (PDF) |
| 260 | Monitoring of Metastatic Breast Cancer Using Circulating Tumour DNA: A Comparison With Circulating Tumour Cells | 9.9 | 0 | Citations (PDF) |
| 261 | A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER‐positive breast cancer | 4.9 | 71 | Citations (PDF) |
| 262 | The landscape of cancer genes and mutational processes in breast cancer | 37.9 | 1,649 | Citations (PDF) |
| 263 | The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups | 37.9 | 5,707 | Citations (PDF) |
| 264 | Biological and prognostic associations of
miR‐205
and
let‐7b
in breast cancer revealed by
in situ
hybridization analysis of micro‐RNA expression in arrays of archival tumour tissue | 4.9 | 74 | Citations (PDF) |
| 265 | Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA | 12.5 | 1,208 | Citations (PDF) |
| 266 | The clonal and mutational evolution spectrum of primary triple-negative breast cancers | 37.9 | 1,926 | Citations (PDF) |
| 267 | Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium | 2.9 | 156 | Citations (PDF) |
| 268 | Cancer stem cell markers in breast cancer: pathological, clinical and prognostic significance | 4.7 | 94 | Citations (PDF) |
| 269 | Comparison of methods for handling missing data on immunohistochemical markers in survival analysis of breast cancer | 5.5 | 65 | Citations (PDF) |
| 270 | Calpastatin is associated with lymphovascular invasion in breast cancer | 2.3 | 33 | Citations (PDF) |
| 271 | The breast cancer genome - a key for better oncology | 2.9 | 9 | Citations (PDF) |
| 272 | ZNF703
is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium | 7.1 | 126 | Citations (PDF) |
| 273 | PathGrid: a service-orientated architecture for microscopy image analysis | 2.5 | 5 | Citations (PDF) |
| 274 | Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules | 2.9 | 158 | Citations (PDF) |
| 275 | Oncogenic KRAS is not necessary for Wnt signalling activation in APC‐associated FAP adenomas | 4.9 | 26 | Citations (PDF) |
| 276 | Driver mutations in
TP53
are ubiquitous in high grade serous carcinoma of the ovary | 4.9 | 723 | Citations (PDF) |
| 277 | From genomic landscapes to personalized cancer management—is there a roadmap? | 4.0 | 16 | Citations (PDF) |
| 278 | Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research | 3.8 | 517 | Citations (PDF) |
| 279 | Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies | 8.0 | 834 | Citations (PDF) |
| 280 | Genomic Architecture Characterizes Tumor Progression Paths and Fate in Breast Cancer Patients | 12.5 | 140 | Citations (PDF) |
| 281 | Micro‐RNAs and breast cancer | 4.1 | 97 | Citations (PDF) |
| 282 | A 4-Gene Signature Predicts Survival of Patients With Resected Adenocarcinoma of the Esophagus, Junction, and Gastric Cardia | 0.9 | 140 | Citations (PDF) |
| 283 | Fine scale mapping of the breast cancer 16q12 locus | 2.9 | 71 | Citations (PDF) |
| 284 | Genetic predisposition to gastro-oesophageal cancer | 3.2 | 56 | Citations (PDF) |
| 285 | Genomic gain of 5p15 leads to over-expression of Misu (NSUN2) in breast cancer | 8.6 | 93 | Citations (PDF) |
| 286 | Common germ-line polymorphism of C1QA and breast cancer survival | 5.5 | 21 | Citations (PDF) |
| 287 | Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601) | 27.4 | 125 | Citations (PDF) |
| 288 | The importance of platform annotation in interpreting microarray data | 27.4 | 16 | Citations (PDF) |
| 289 | CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen | 4.7 | 80 | Citations (PDF) |
| 290 | PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer | 4.7 | 366 | Citations (PDF) |
| 291 | Systematic comparison of microarray profiling, real-time PCR, and next-generation sequencing technologies for measuring differential microRNA expression | 3.8 | 632 | Citations (PDF) |
| 292 | Germline CDH1 deletions in hereditary diffuse gastric cancer families | 2.9 | 198 | Citations (PDF) |
| 293 | Characterisation of microRNA expression in post-natal mouse mammary gland development | 3.3 | 120 | Citations (PDF) |
| 294 | The pitfalls of platform comparison: DNA copy number array technologies assessed | 3.3 | 82 | Citations (PDF) |
| 295 | Common germline polymorphisms in COMT, CYP19A1, ESR1, PGR, SULT1E1 and STS and survival after a diagnosis of breast cancer | 4.3 | 34 | Citations (PDF) |
| 296 | A metadata approach for clinical data management in translational genomics studies in breast cancer | 1.7 | 30 | Citations (PDF) |
| 297 | Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution | 37.9 | 1,009 | Citations (PDF) |
| 298 | Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival | 5.5 | 81 | Citations (PDF) |
| 299 | Extent of differential allelic expression of candidate breast cancer genes is similar in blood and breast | 4.7 | 34 | Citations (PDF) |
| 300 | Dysregulated expression of Fau and MELK is associated with poor prognosis in breast cancer | 4.7 | 139 | Citations (PDF) |
| 301 | Alpha‐6 integrin is necessary for the tumourigenicity of a stem cell‐like subpopulation within the MCF7 breast cancer cell line | 4.3 | 195 | Citations (PDF) |
| 302 | ESR1 gene amplification in breast cancer: a common phenomenon? | 25.2 | 63 | Citations (PDF) |
| 303 | Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer | 2.9 | 171 | Citations (PDF) |
| 304 | High-resolution array CGH clarifies events occurring on 8p in carcinogenesis | 2.9 | 42 | Citations (PDF) |
| 305 | Array Comparative Genomic Hybridization Copy Number Profiling: A New Tool for Translational Research in Solid Malignancies | 2.7 | 47 | Citations (PDF) |
| 306 | A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the Proliferation, Immune response and RNA splicing modules in breast cancer | 4.7 | 116 | Citations (PDF) |
| 307 | A robust classifier of high predictive value to identify good prognosis patients in ER-negative breast cancer | 4.7 | 92 | Citations (PDF) |
| 308 | Effects of common germline genetic variation in cell cycle control genes on breast cancer survival: results from a population-based cohort | 4.7 | 35 | Citations (PDF) |
| 309 | PMC42, a breast progenitor cancer cell line, has normal-like mRNA and microRNA transcriptomes | 4.7 | 22 | Citations (PDF) |
| 310 | DNA repair polymorphisms and the risk of stomach adenocarcinoma and severe chronic gastritis in the EPIC-EURGAST study | 4.9 | 70 | Citations (PDF) |
| 311 | Allele-Specific Up-Regulation of FGFR2 Increases Susceptibility to Breast Cancer | 5.0 | 260 | Citations (PDF) |
| 312 | Elucidating the Altered Transcriptional Programs in Breast Cancer using Independent Component Analysis | 3.1 | 110 | Citations (PDF) |
| 313 | Pathology findings and validation of gastric and esophageal cancer cases in a European cohort (EPIC/EUR-GAST) | 1.7 | 46 | Citations (PDF) |
| 314 | Cancer genetics of epigenetic genes | 2.9 | 233 | Citations (PDF) |
| 315 | Regulation of p53 tetramerization and nuclear export by ARC | 7.5 | 105 | Citations (PDF) |
| 316 | Common Germline Genetic Variation in Antioxidant Defense Genes and Survival After Diagnosis of Breast Cancer | 16.9 | 105 | Citations (PDF) |
| 317 | High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer | 12.2 | 290 | Citations (PDF) |
| 318 | MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype | 12.2 | 860 | Citations (PDF) |
| 319 | An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer | 12.2 | 449 | Citations (PDF) |
| 320 | Co‐amplification of 8p12 and 11q13 in breast cancers is not the result of a single genomic event | 3.0 | 27 | Citations (PDF) |
| 321 | Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis | 60.7 | 420 | Citations (PDF) |
| 322 | The Extracellular Matrix Protein TGFBI Induces Microtubule Stabilization and Sensitizes Ovarian Cancers to Paclitaxel | 33.0 | 216 | Citations (PDF) |
| 323 | MicroRNA—implications for cancer | 2.9 | 393 | Citations (PDF) |
| 324 | Title is missing! | 12.2 | 82 | Citations (PDF) |
| 325 | ZNF198, a zinc finger protein rearranged in myeloproliferative disease, localizes to the PML nuclear bodies and interacts with SUMO-1 and PML | 3.1 | 35 | Citations (PDF) |
| 326 | High-Resolution Magic Angle Spinning1H NMR Spectroscopy and Reverse Transcription-PCR Analysis of Apoptosis in a Rat Glioma | 6.5 | 51 | Citations (PDF) |
| 327 | Comparative genomic hybridization of esophageal adenocarinoma and squamous cell carcinoma cell lines | 0.5 | 10 | Citations (PDF) |
| 328 | Familial gastric cancer – clinical management | 2.7 | 20 | Citations (PDF) |
| 329 | Familial gastric cancer – aetiology and pathogenesis | 2.7 | 37 | Citations (PDF) |
| 330 | Genomic imbalances and patterns of karyotypic variability in mantle-cell lymphoma cell lines | 0.7 | 46 | Citations (PDF) |
| 331 | Pharmacogenetics of cancer chemotherapy | 7.0 | 22 | Citations (PDF) |
| 332 | Differential expression of selected histone modifier genes in human solid cancers | 3.3 | 218 | Citations (PDF) |
| 333 | PACK: Profile Analysis using Clustering and Kurtosis to find molecular classifiers in cancer | 4.7 | 63 | Citations (PDF) |
| 334 | Optimal Amounts of Fluorescent Dye Improve Expression Microarray Results in Tumor Specimens | 2.0 | 4 | Citations (PDF) |
| 335 | Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer | 25.2 | 1,804 | Citations (PDF) |
| 336 | A 1 Mb minimal amplicon at 8p11–12 in breast cancer identifies new candidate oncogenes | 6.5 | 149 | Citations (PDF) |
| 337 | Chromosome abnormalities in 10 lung cancer cell lines of the NCI-H series analyzed with spectral karyotyping | 1.2 | 33 | Citations (PDF) |
| 338 | Identification and validation of prognostic markers in breast cancer with the complementary use of array‐CGH and tissue microarrays | 4.9 | 138 | Citations (PDF) |
| 339 | Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer | 2.8 | 42 | Citations (PDF) |
| 340 | A variational Bayesian mixture modelling framework for cluster analysis of gene-expression data | 4.7 | 76 | Citations (PDF) |
| 341 | Human and mouse oligonucleotide-based array CGH | 15.5 | 233 | Citations (PDF) |
| 342 | Chromatin modifier enzymes, the histone code and cancer | 4.9 | 295 | Citations (PDF) |
| 343 | Molecular Classification and Molecular Forecasting of Breast Cancer: Ready for Clinical Application? | 16.9 | 847 | Citations (PDF) |
| 344 | Elucidating the Altered Transcriptional Programs in Breast Cancer using Independent Component Analysis | 3.1 | 0 | Citations (PDF) |
| 345 | Microarray segmentation methods significantly influence data precision | 15.5 | 57 | Citations (PDF) |
| 346 | p300 regulates p53-dependent apoptosis after DNA damage in colorectal cancer cells by modulation of PUMA/p21 levels | 7.5 | 137 | Citations (PDF) |
| 347 | Novel human, mouse and xenopus genes encoding a member of the RAS superfamily of low-molecular-weight GTP-binding proteins and its downregulation in W/WV mouse jejunum | 2.5 | 8 | Citations (PDF) |
| 348 | p300/CBP and cancer | 6.5 | 606 | Citations (PDF) |
| 349 | Expression microarray reproducibility is improved by optimising purification steps in RNA amplification and labelling | 3.3 | 45 | Citations (PDF) |
| 350 | Model of the early development of diffuse gastric cancer in E‐cadherin mutation carriers and its implications for patient screening | 4.9 | 251 | Citations (PDF) |
| 351 | Gastric Cancer — Keeping It in the Family | 0.0 | 1 | Citations (PDF) |
| 352 | Differential gene expression in the murine gastric fundus lacking interstitial cells of Cajal | 2.2 | 28 | Citations (PDF) |
| 353 | Differential gene expression profile in the small intestines of mice lacking pacemaker interstitial cells of Cajal | 2.2 | 12 | Citations (PDF) |
| 354 | A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma | 0.9 | 465 | Citations (PDF) |
| 355 | EMSY Links the BRCA2 Pathway to Sporadic Breast and Ovarian Cancer | 33.6 | 406 | Citations (PDF) |
| 356 | Identification of CDH1 germline missense mutations associated with functional inactivation of the E-cadherin protein in young gastric cancer probands | 2.9 | 171 | Citations (PDF) |
| 357 | Genetic screening for hereditary diffuse gastric cancer | 3.0 | 46 | Citations (PDF) |
| 358 | Molecular Classification of Breast Carcinomas Using Tissue Microarrays | 1.4 | 158 | Citations (PDF) |
| 359 | A simple and reliable pretreatment protocol facilitates fluorescent in situ hybridisation on tissue microarrays of paraffin wax embedded tumour samples | 2.2 | 85 | Citations (PDF) |
| 360 | Helicobacter pylori and Interleukin 1 Genotyping: An Opportunity to Identify High-Risk Individuals for Gastric Carcinoma | 4.6 | 580 | Citations (PDF) |
| 361 | Reply | 0.9 | 2 | Citations (PDF) |
| 362 | Screening E-cadherin in gastric cancer families reveals germline mutations only in hereditary diffuse gastric cancer kindred | 4.5 | 156 | Citations (PDF) |
| 363 | Interleukin 1B and interleukin 1RN polymorphisms are associated with increased risk of gastric carcinoma | 0.9 | 409 | Citations (PDF) |
| 364 | Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families | 0.9 | 616 | Citations (PDF) |
| 365 | Early Gastric Cancer in Young, Asymptomatic Carriers of Germ-Line E-Cadherin Mutations | 34.5 | 443 | Citations (PDF) |
| 366 | Title is missing! | 4.7 | 33 | Citations (PDF) |
| 367 | Degenerate Oligonucleotide Primed-Polymerase Chain Reaction-Based Array Comparative Genomic Hybridization for Extensive Amplicon Profiling of Breast Cancers | 3.4 | 99 | Citations (PDF) |
| 368 | Prophylactic total gastrectomy for familial gastric cancer | 1.8 | 156 | Citations (PDF) |
| 369 | MLL2, the second human homolog of the Drosophila trithorax gene, maps to 19q13.1 and is amplified in solid tumor cell lines | 6.5 | 103 | Citations (PDF) |
| 370 | Expression and protein-binding studies of the EEN gene family, new interacting partners for dynamin, synaptojanin and huntingtin proteins | 3.8 | 29 | Citations (PDF) |
| 371 | Mutations truncating the EP300 acetylase in human cancers | 25.2 | 570 | Citations (PDF) |
| 372 | Design and synthesis of germline-based hemi-humanized single-chain Fv against the CD18 surface antigen | 2.6 | 25 | Citations (PDF) |
| 373 | Report on the First Meeting of the International Collaborative Group on Hereditary Gastric Cancer | 4.6 | 42 | Citations (PDF) |
| 374 | Title is missing! | 12.2 | 18 | Citations (PDF) |
| 375 | Biliopancreatic malignancy: Screening the at risk patient with molecular markers | 9.9 | 8 | Citations (PDF) |
| 376 | Analysis of the region of the 5' end of the MLL gene involved in genomic duplication events | 2.7 | 14 | Citations (PDF) |
| 377 | Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis | 5.5 | 276 | Citations (PDF) |
| 378 | Title is missing! 1999, 18, 313-329 | | 25 | Citations (PDF) |
| 379 | Evidence for a role of FGF-2 and FGF receptors in the proliferation of non-small cell lung cancer cells 1999, 83, 415-423 | | 96 | Citations (PDF) |
| 380 | Isolation and characterization of a Pufferfish MLL (Mixed lineage leukemia)-like gene (fMll) reveals evolutionary conservation in vertebrate genes related to Drosophila trithorax | 6.5 | 32 | Citations (PDF) |
| 381 | Exon scrambling of MLL transcripts occur commonly and mimic partial genomic duplication of the gene | 2.3 | 75 | Citations (PDF) |
| 382 | Molecular assessment of cancer | 0.1 | 11 | Citations (PDF) |
| 383 | EEN encodes for a member of a new family of proteins containing an Src homology 3 domain and is the third gene located on chromosome 19p13 that fuses to MLL in human leukemia | 7.5 | 122 | Citations (PDF) |
| 384 | Aberrant splicing of the TSG101 and FHIT genes occurs frequently in multiple malignancies and in normal tissues and mimics alterations previously described in tumours | 6.5 | 80 | Citations (PDF) |
| 385 | Epstein-Barr virus and bone marrow transplantation | 2.1 | 14 | Citations (PDF) |
| 386 | Molecular genetics of pancreatic carcinoma | 1.2 | 2 | Citations (PDF) |
| 387 | K-ras mutation and pancreatic adenocarcinoma | 0.8 | 140 | Citations (PDF) |
| 388 | Common occurrence of APC and K-ras gene mutations in the spectrum of colitis-associated neoplasias | 0.9 | 143 | Citations (PDF) |
| 389 | Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma | 25.2 | 1,088 | Citations (PDF) |
| 390 | Molecular genetic profiles of colitis-associated neoplasms | 0.9 | 155 | Citations (PDF) |
| 391 | Case Report: Transverse Myelitis Associated With Epstein-Barr Virus Infection | 0.9 | 42 | Citations (PDF) |
| 392 | SALVAGE THERAPY IN EPITHELIAL OVARIAN CANCER | 1.9 | 5 | Citations (PDF) |
| 393 | Synchronous mature teratomas of the ovary and liver: A case presenting 11 years following chemotherapy for immature teratoma | 3.0 | 31 | Citations (PDF) |
| 394 | Global transcriptional analysis identifies a novel role for SOX4 in tumor-induced angiogenesis | 0.7 | 51 | Citations (PDF) |
| 395 | A large‐scale retrospective study in metastatic breast cancer patients using circulating tumour
DNA
and machine learning to predict treatment outcome and progression‐free survival | 4.1 | 5 | Citations (PDF) |
| 396 | Detecting homologous recombination deficiency for breast cancer through integrative analysis of genomic data | 4.1 | 0 | Citations (PDF) |
